Drugs / TAPA-pulsed DC vaccine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02223312 | Jul 2017 → Oct 2018 | cancer, hematopoietic and lymphoid cell neoplasm | Kiromic BioPharma Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02709993 | Jul 2017 → Oct 2020 | cancer, hematopoietic and lymphoid cell neoplasm | Kiromic BioPharma Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02705703 | Jul 2017 → Oct 2018 | metastatic malignant neoplasm | Kiromic BioPharma Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02224599 | Jul 2017 → Aug 2018 | cancer | Kiromic BioPharma Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAPA-pulsed DC vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02705703 ↗ |
| Modality | Cell therapy | “TAPA-pulsed dendritic cell therapy” NCT02224599 ↗ |
| Route | Subcutaneous | “DC vaccination schedule will be once every fourteen (14) days via subcutaneous (SC) and intradermal (ID) injections” NCT02223312 ↗ |